
Full text loading...
Category: Bacterial Pathogenesis; Clinical Microbiology
Mycobacterium bovis BCG and New Vaccines for the Prevention of Tuberculosis, Page 1 of 2
< Previous page | Next page > /docserver/preview/fulltext/10.1128/9781555819866/9781555819859_Chap11-1.gif /docserver/preview/fulltext/10.1128/9781555819866/9781555819859_Chap11-2.gifAbstract:
A critical component of global tuberculosis control is the development of more effective immunization strategies. Several tuberculosis vaccines have been shown to reduce the risk of disease and death due to tuberculosis in humans, but only one is used in global immunization programs: Mycobacterium bovis bacillus Calmette-Guérin (BCG). BCG is an attenuated live vaccine administered at birth to children in most countries where tuberculosis is endemic. BCG has been the most widely administered vaccine in the world, with an estimated three billion doses administered to date ( 1 ). BCG has likely reduced the burden of tuberculosis in many areas, but it has numerous limitations. These limitations, together with the continuation of the global tuberculosis epidemic, have made the development of a more effective vaccine against tuberculosis a major international public health priority ( 2 , 3 ).
Full text loading...
Selected vaccines in advanced human clinical trials. P, clinical trial demonstrated protection from tuberculosis; F, clinical trial failed to show protection from tuberculosis. Based on references 127 , 135 to 138 , 191 , 202 , and 203 .
Selected vaccines in advanced human clinical trials. P, clinical trial demonstrated protection from tuberculosis; F, clinical trial failed to show protection from tuberculosis. Based on references 127 , 135 to 138 , 191 , 202 , and 203 .